Thomas Dörner, MD, reviewed the current state of systemic lupus erythematosus (SLE) management, providing updates on novel therapies and insights into the pathogenesis of SLE.
New HCPCS Code Added for Anifrolumab-fnia, 1 mg
Effective for dates of service on or after April 1, the Healthcare Common Procedure Coding System (HCPCS) code J0491 is valid for billing 1 mg anifrolumab-fnia.
Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus
ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric…
A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review
During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.
In Wake of Lupus Trial Failure, New Research Attacks From Many Angles
CHICAGO—When Richard Furie, MD, was first asked to speak about lupus at the 2019 ACR State-of-the-Art Clinical Symposium, held April 5–7, organizers suggested he discuss low disease activity and classification criteria. But Dr. Furie, a professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y., and a veteran investigator…
The Type I Interferon Pathway’s Influence in Connective Tissue Disease
Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…
Insight into Clinical Trials for Lupus
Research into lupus treatments suffered a setback after the failure of anifrolumab in clinical trials. However, during the 2019 ACR State-of-the-Art Clinical Symposium, Richard Furie, MD, outlined the possibilities of multiple new lupus therapies under investigation…
AstraZeneca Lupus Drug Fails to Meet Main Goal in Study
(Reuters)—AstraZeneca’s experimental drug anifrolumab failed to meet its main target in a late-stage clinical study treating patients with moderate to severe lupus, the British drugmaker said on Friday. AstraZeneca said the drug did not meet the main goal in the final-stage of one of the two clinical trials under the TULIP program, failing to show…
Effectiveness of Novel Therapies for Cutaneous SLE Explored
WASHINGTON, D.C.—A new, humanized anti-BDCA2 monoclonal antibody can trigger inhibition of the production of interferon, cytokines and chemokines derived from plasmacytoid dendritic cells in patients with cutaneous systemic lupus erythematosus (SLE), according to research presented at the 2016 ACR/ARHP Annual Meeting. The findings were discussed during a session on SLE treatment, drug adherence and the…
New SLE Drug May Allow Patients to Reduce Steroid Use
In a recent study, the use of anifrolumab in SLE patients was shown to be safe and effective, enabling some patients to decrease their oral steroids. Also, secukinumab has been approved in Europe to treat ankylosing spondylitis and psoriatic arthritis…